Premier Alternatives

Cellens

Decision/Risk Analysis · Boston, MA · Founded 2019 · Privately Held (backing)

Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. Cellens is based in Boston, MA and was founded in 2019. It was valued at $19.4 million at its early-stage round in Aug 2025, the last priced event on record. It has raised $7.5 million across 3 recorded rounds; the latest was a $6.4 million early-stage round in Aug 2025.

PMV mark · valuation
$19.4M
Oct 2026
Priced at
its early-stage round
Aug 2025
Total raised
$7.5M
Last round
Early Stage VC
Aug 2025

Cellens key facts

as of Oct 2026
  • Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer.
  • Cellens is valued at approximately $19.4M as of Oct 2026, set at its early-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $7.5M across 3 recorded rounds; the latest was Early Stage VC ($6.4M) in Aug 2025.
  • Notable investors include Creative Destruction Lab, SOSV, Springboard Enterprises, IndieBio, VentureWell — 19 tracked in total.
  • Cellens has filed 2 Form Ds with the SEC since 2022, most recently Nov 2025 ($6.4M sold to 33 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$19.4M

Valued at $19.4M at its early-stage round, Aug 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Cellens with a free account
  • ·The complete investor list: 19 names
  • ·Watch Cellens: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cellens funding rounds

3 rounds
Aug 2025Early Stage VC$6.4MSEC filing▮
Sep 2024Accelerator/Incubator—▮
Apr 2022Debt$585KSEC filing▮
Full funding history →

Cellens valuation

Cellens was valued at $19.4 million at its early-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Cellens raised?

Cellens has raised $7.5 million across 3 recorded rounds since 2022. The largest was a $6.4 million early-stage round in Aug 2025.

Cellens has filed 2 Form Ds with the SEC since 2022, most recently in Nov 2025 ($6.4 million sold to 33 investors).

Cellens investors

19 investors are on record for Cellens, including Creative Destruction Lab, SOSV, Springboard Enterprises and IndieBio. The early-stage round in Aug 2025 drew 33 investors.

Comparable companies

Comparable decision/risk analysis names by valuation on PrivateMarketView: Anumana ($580 million), VideaHealth ($400 million) and Inductive Bio ($80 million).

About Cellens

Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. The company's platform leverages the power of atomic force microscopy imaging and machine learning modeling to perform tests that quantify physio-biomarkers on cell surfaces extracted from urine samples to provide a diagnostic score for bladder cancer, enabling oncologists, urologists, and healthcare providers to reduce invasive, costly, and inaccurate procedures of bladder cancer diagnostics to optimize patient survival experience.

Industry
Decision/Risk Analysis
Sector
Healthcare
HQ
Boston, MA, United States
Founded
2019
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.